Background: Due to satisfactory cytoreductive surgery combined with platinum-based chemotherapy in epithelial ovarian cancer has improved greatly, however, the relapse rate also high. In current study, we analyzed prognostic factors related to secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer.
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INTRODUCTION
Epithelial ovarian cancer is one of the common gynecological malignancies. The five-year survival rate in epithelial ovarian cancer has improved greatly due to satisfactory cytoreductive surgery combined with platinum-based chemotherapy. However, even after systemic treatment involving surgery with chemotherapy, the relapse rate at the early stages of epithelial ovarian cancer is still 20%-25%, while that at the advanced stages can be as high as 70% [1] . The treatment procedure after relapse is mainly chemotherapy, although surgery can also be performed on a proportion of patients. Reports on the prognosis of patients with recurrent epithelial ovarian cancer who underwent secondary cytoreductive surgery are inconsistent. In this study, a total of 103 patients from our hospital with recurrent epithelial ovarian cancer who underwent secondary cytoreductive surgery were included. Their surgical conditions were analyzed retrospectively, including clinical and pathological data, recurrence condition, and conditions of secondary surgery, in order to explore the factors related to the prognosis of patients with recurrent epithelial ovarian cancer who underwent secondary cytoreductive surgery.
METHODS
Basic information
A total of 103 patients with recurrent epithelial ovarian cancer, who received secondary cytoreductive surgery and were admitted to the Department of Gynecology at the Fourth Hospital of Hebei Medical University between January 2000 and December 2008, were selected as subjects for this study. Detailed records were kept, which included the age of onset, condition of residual tumor after the first surgery, tumor pathology, pathological staging, recurrence conditions, and conditions of secondary surgery. All patients underwent surgery and 6-8 courses of platinum-based adjuvant chemotherapy for their first treatment, as well as secondary cytoreductive surgery after relapse followed by systemic adjuvant chemotherapy. Responders (platinum-sensitive) were defined as an ovarian cancer patient who had a treatment-free interval greater than 6 months from the last date of the initial six cycles of platinum-based combination chemotherapy. A nonresponder (platinum-resistance) was defined as an ovarian cancer patient who had a treatment-free interval less than 6 months from the last date of the initial six cycles of platinum-based combination chemotherapy, including disease that had progressed during chemotherapy. All patients were followed-up until October 2012.
Conditions of secondary surgery
All 103 patients underwent surgery for their first treatment and after recurrence, which was followed by adjuvant chemotherapy. Selection of patients with recurrent epithelial ovarian cancer, DFI ≥ 12 months and a single lesion, as well as achieving satisfactory cytoreduction or even removing all visible residual tumors as much as possible. Based on the condition of residual tumor during surgery, patients were divided into groups: no visible residual tumor, residual tumor with diameter < 1 cm and residual tumor with diameter ≥ 1 cm, whereby residual tumor < 1 cm was classified as satisfactory cytoreduction.
Disease free interval, survival after recurrence and overall survival
DFI refers to the interval between the day of the last chemotherapy treatment and disease relapse.
Based on the treatment-free interval before secondary cytoreductive surgery, patients were divided into two groups: treatment-free interval ≥ 12 months and treatment-free interval < 12 months. RS refers to the interval between the day of recurrence diagnosis and death or the last follow-up. OS refers to the interval between the day of diagnosis and death or the last follow-up.
Statistical analysis
Measurement data were described using median, mean and standard deviation. Count data were described using ratio and percentage. SPSS 19.0 (SPSS, Chicago, IL, USA) was used for statistical analysis. Survival times were analyzed using Kaplan-Meier estimator and Cox regression model; differences were tested using the Log-rank test. P < 0.05 indicated statistical significance. Table 1 , the median age of the 103 patients at disease onset was 49 years old, of which the youngest was 29 years old and the oldest was 74 years old. At the end of follow-up, 68.9% (71/103) had died and 31.1% (32/103) survived; OS was 20-114 months, and the median OS was 60 months.
RESULTS
Basic patient information at first treatment
As shown in
Conditions at secondary cytoreductive surgery after relapse
As shown in Table 2 , the median RS of the 103 patients after the first relapse was 36 months. 
Univariate analysis of factors influencing RS and OS
Using RS and OS as the dependent variables, univariate analyses were conducted to examine various factors that might have influenced the patients' RS and OS ( Table 3 ). Univariate analysis of age, pathology type, differentiation degree, residual tumor at first surgery, chemotherapy before cytoreductive surgery, CA-125 before secondary cytoreductive surgery, ascites before secondary cytoreductive surgery and maximum size of lesion at relapse did not reveal clear correlations with RS and OS. FIGO stage, DFI at secondary cytoreductive surgery, number of lesions at relapse and residual tumor at secondary cytoreductive surgery were correlated with the patients' RS and OS.
Multivariate Cox regression analysis
Univariate analysis revealed that FIGO stage was correlated with patients' RS and OS. However, multivariate analysis did not show statistical significance, which may due to a small number of stage Ⅰand Ⅱ patients. Results from multivariate Cox regression analysis suggested that DFI for secondary cytoreductive surgery, number of lesions at recurrence and residual tumor at secondary cytoreductive surgery were all correlated with patients' RS and OS (Table 4) . Hence, these are independent factors influencing the prognosis of patients with epithelial ovarian cancer who underwent secondary cytoreductive surgery.
DISCUSSION
The treatment for recurrent epithelial ovarian cancer is mainly chemotherapy, but surgery can also be performed on a proportion of patients. By reviewing the results of previous studies on the analysis of factors influencing the prognosis of patients who underwent secondary cytoreductive surgery, we found that aside from the conditions of residual tumor at secondary cytoreductive surgery, there still remains much controversy amongst the effects on prognosis of factors such as DFI, number of tumor recurrence, ascites, histology type, tumor recurrence site, maximum diameter of recurrent tumors, and the presence of chemotherapy after secondary cytoreductive surgery [2] .
In patients with epithelial ovarian cancer who received first surgical treatment, satisfactory cytoreductive surgery, especially those without visible residual tumors, significantly correlated [3] . Similar situation has also been observed in patients with recurrent epithelial ovarian cancer who underwent surgical treatment. The DESKTOP Ⅰexperiment [4] retrospectively analyzed the data from 267 cases of recurrent epithelial ovarian cancer found that the difference in the OS of patients with tumors between 0.1-1 cm and those greater than 1 cm was not statistically significant, and complete tumor resection was an independent contributing factor for RS [5] . Zang et al. [6] once again demonstrate that satisfactory cytoreduction, especially those without visible residual tumors, ensured a good prognosis. Various local and international researchers [7] [8] [9] have also expressed a similar viewpoint. Our study indicates that satisfactory cytoreduction (< 1 cm) was achieved when the size of the residual tumor was between 0.1-1 cm with relatively good prognosis. Similar to primary cytoreductive surgery, the efficacy of chemotherapy after secondary cytoreductive surgery was related to the number of residual tumor cells.
Previously researchers reported that DFI was one of predict the OS of patients with recurrent epithelial ovarian cancer [10] . The authors posited that the longer the DFI, the longer the patient's OS. In regard to the prognosis after secondary cytoreductive surgery in recurrent ovarian cancer, Tian et al. [11] found that patients with disease free interval(DFI) < 16 months accounted for 39.3% , amongst which 27.7% had complete tumor resection, while patients with DFI ≥ 16 months accounted for 60.7%, amongst which 48.6% had complete tumor resection; there was a statistically significant difference between the two groups, suggesting that the longer the DFI, the higher the rate of complete tumor resection. Zang et al. [6] reported that after secondary cytoreductive surgery, patient prognosis was related to four factors, of which the median OS of patients with DFI 6-23.1 months and < 23.1 months were 45.0 months and 21.0 months, suggesting that the longer the treatment-free interval, the longer the OS and the better the prognosis. Other local and international researchers [7, 9, 12, 13] have also agreed with this viewpoint. However, nearly half of the reports [2] indicated that DFI was not correlated with the OS of patients who had undergone secondary cytoreductive surgery. For example, the DESKTOP Ⅰ [4] experiment discovered that using multivariate analysis, the length of the DFI was not an independent contributing factor for the prognosis of secondary cytoreductive surgery. Zang et al. [14] also reported that DFI length affected prognosis in univariate analysis, but this was not confirmed in multivariate analysis. There are other researchers who also believe that DFI is not significantly correlated with the postoperative survival time of patients after secondary cytoreductive surgery [15, 16] . It was found in this study that DFI before secondary cytoreductive surgery ≥ 12 months accounted for 66.0% (68/103), while DFI < 12 months accounted for 34% M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 6 (35/103). The median RS and OS for the group with DFI ≥ 12 months were 40 and 72 months, respectively, while that for the group with DFI < 12 months were 28 and 53 months, respectively.
Multivariate Cox regression analysis revealed statistically significant differences between the two groups (HR = 1.893, 95% CI = 0.455-2.630; P = 0.028, HR = 2.446, 95% CI = 1.239-4.828, P = 0.011). We can therefore conclude that DFI was significantly correlated with patient prognosis: the longer the DFI of the recurrent patient, the longer the post-operative RS and OS.
Chi et al. [12] found that the median survival times for secondary cytoreduction patients who had single-site lesion, multi-site lesion and carcinomatosis were 60, 42 and 28 months, respectively.
Multivariate analysis revealed that the number of lesions was an independent prognostic factor for recurrent epithelial cancer. Zang et al. [6] found that the OS of patients with ≤ 3 lesions and > 3 lesions were 43.9 and 20 months, respectively. Patients with ≤ 3 recurrent lesions had longer post-operative OS. However, some [7, 15] also believe that the number of recurrent lesions does not affect surgical outcome and patient prognosis. In this study, statistical results revealed that the number of patients with one recurrent lesion accounted for 27.2% (28/103), for which the median RS and OS were 48 and 71 months, respectively. Patients with two or more recurrent lesions accounted for 72.8% (75/103), for which the median RS and OS were 30 and 52 months, respectively. Univariate and multivariate analyses showed significant differences between these two groups (P < 0.05); the median RS and OS of the patients with one lesion were longer than that of the patients with two or more lesions. Taken together with previous reports, we can conclude that the fewer the recurrent lesions, the better the patient's prognosis.
In 1983, Berek et al. [17] first proposed the concept of secondary cytoreductive surgery for recurrent ovarian cancer, in hopes of reducing tumor load, improving quality of life and alleviating tumor-related symptoms, thereby elevating survival rate. In recent years, numerous domestic and international studies have reported that surgical treatment of recurrent epithelial ovarian cancer can significantly prolong survival. An increasing number of researchers believe that surgical treatment should be performed where possible in patients with recurrent epithelial ovarian cancer that is platinum-sensitive and where complete resection is possible. The NCCN [18] guidelines have also suggested that surgical treatment is an option for patients with chemotherapy-free intervals > 6 months if the tumor is localized and satisfactory cytoreduction is possible. NCCN guideline has indications for secondary cytoreductive surgery: DFI>12 month, no ascite, one lesion of recurrence. However, occurrence rate of perioperative complications and mortality rate of secondary surgical procedures for epithelial ovarian cancer are relatively high [19] , and hence the careful selection of suitable patients is extremely important. A few scholars M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7 have outlined a set of selection criteria for secondary surgery in recurrent epithelial ovarian cancer: (1) an interval greater than 12 months between the end of the first treatment and recurrence, (2) good response to previous chemotherapy, (3) possibility of complete tumor resection, (4) in good general condition, (5) and younger patients [20, 21] .
In the past few years, great emphasis has been placed on the importance of a series of DESKTOP OVAR trials investigating pre-operative prediction of whether secondary cytoreductive surgery in recurrent epithelial ovarian cancer can achieve complete tumor resection. The experiments proposed a scoring system to evaluate whether surgical treatment would be able to achieve a lack of visible residual tumors in epithelial ovarian cancer, in order provide important reference for the selection of patients for secondary cytoreductive surgery. Results of the DESKTOP Ⅰ retrospective clinical study pointed out that amongst patients with Eastern Cooperative Oncology Group (ECOG) score of 0 points, absence of residual tumor at first surgery or at clinical stage Ⅰ/Ⅱ, and ascites < 500 ml at supplementary examination after recurrence, 79% achieved complete resection during the secondary surgery. The DESKTOP Ⅱ [22] trial verified the abovementioned scoring system in a prospective study, showing that amongst patients with good survival status (ECOG score = 0), absence of visible residual tumors at the first surgery, and ascites < 500 ml at supplementary examination after recurrence, 76% achieved complete tumor resection; these patients were ideal candidates for secondary cytoreductive surgery. DESKTOP Ⅲ
is a prospective, multi-center, randomized trial for the continued evaluation of this scoring system.
Tian et al. [11] analyzed cases from multi-center surgical treatments of recurrent epithelial ovarian cancer; 1075 cases were included in the study, of which 40.4% (434/1075) achieved complete tumor resection. This study discovered that there were six factors which predicted whether complete tumor resection could be achieved: FIGO stage, residual tumor at primary surgery, DFI, ECOG score, CA-125 level and presence of ascites at recurrence. The DESKTOP trial series and the report by Tian predicted whether secondary cytoreductive surgery could achieve complete tumor resection using unique scoring systems, thus providing reference criteria for the selection of patients for secondary surgery.
In this study, we found that residual tumor condition at secondary cytoreductive surgery, PFI and number of recurrent lesions were correlated with the RS and OS of patients with epithelial ovarian cancer who underwent secondary cytoreductive surgery. Selection of patients with recurrent epithelial ovarian cancer, DFI ≥ 12 months and a single lesion, as well as achieving satisfactory cytoreduction or even removing all visible residual tumors as much as possible will increase patient survival. Evidently, this study is similar to most other studies on secondary 
